Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.

Hiroya TaniguchiKentaro YamazakiToshiki MasuishiTakeshi KawakamiYusuke OnozawaKazunori HondaShigenori KadowakiYukiya NaritaTakahiro TsushimaSatoshi HamauchiAkiko Todaka Tomoya YokotaMasashi AndoKeita MoriHiromichi ShirasuHirofumi YasuiKei Muro

Published in: The oncologist (2023)

Biweekly trifluridine/tipiracil, irinotecan, and bevacizumab administration may have moderate antitumor activity with high risk of severe myelotoxicity in previously treated patients with metastatic colorectal cancer [UMIN Clinical Trials Registry (UMIN000019828) and Japan Registry of Clinical Trials (jRCTs041180028)].

Keyphrases

metastatic colorectal cancer
clinical trial
phase ii
open label
high intensity
early onset
phase iii
double blind
study protocol